The experimental physiologist Carl Ludwig (1816-1895): Scientific genius - modest, selfless, unswerving!
Pneumologie. 2024 Apr 24. doi: 10.1055/a-2293-1235. Online ahead of print.ABSTRACTCarl Ludwig was, besides Johannes Müller, one of the most prolific natural scientists of the 19th century. Carl Ludwig believed that the function of organs can be ascribed to the laws of physics and chemistry and that only through repeatable physiological experiments can hypotheses be verified. Ludwig has laid the technological foundations for experimental physiology. The "kymographion", (waves-recorder), the "stromuhr" and the blood gas pump are some of his developments that underline this fact. Together with his students he performed funda...
Source: Pneumologie - April 24, 2024 Category: Respiratory Medicine Authors: Ulrich Koehler Andreas Weissflog Source Type: research
Hepatitis E and diaphragmatic dysfunction: Case series and review of the literature
CONCLUSION: NA that shows involvement of the phrenic nerve resulting in diaphragmatic dysfunction and dyspnoea, may be associated with HEV infection. The observation of 13 patients with diaphragmatic dysfunctions and HEV infection within a period of three years indicates a high number of undetected HEV-associated diaphragmatic dysfunction in the population, especially in the absence of NA symptoms. Therefore, even in diaphragmatic dysfunction without NA symptoms and causative damaging event, HEV infection should be considered, as it may represent a subform of NA with only phrenic nerve involvement. Therapy of HEV-associate...
Source: Pneumologie - April 24, 2024 Category: Respiratory Medicine Authors: Michael Westhoff Andres Arias Patric Litterst Source Type: research
Criteria for inpatient diagnostic and treatment of patients with lung cancer, mesothelioma or thymoma
Pneumologie. 2024 Apr;78(4):233-235. doi: 10.1055/a-2227-3775. Epub 2024 Jan 4.NO ABSTRACTPMID:38608657 | DOI:10.1055/a-2227-3775 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Nikolaj Frost Claas Wesseler Bernhard W örmann Wilfried Ernst Erich Eberhardt Source Type: research
Clinical course of mild-to-moderate idiopathic pulmonary fibrosis during therapy with pirfenidone: Results of the non-interventional study AERplus
CONCLUSIONS: The results of this study are in line with the established benefit-risk profile of pirfenidone. Therefore, pirfenidone can be considered a valuable treatment option to slow disease progression in mild-to-moderate idiopathic pulmonary fibrosis. NCT02622477.PMID:38608658 | PMC:PMC11014748 | DOI:10.1055/a-2267-2074 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Jens Schreiber Wolfgang Sch ütte Wolfgang Koerber Bernd Seese Dirk Koschel Kathrin Neuland Christian Groh é Source Type: research
Test Your Knowledge
Pneumologie. 2024 Apr;78(4):276-278. doi: 10.1055/a-2267-9473. Epub 2024 Apr 12.NO ABSTRACTPMID:38608659 | DOI:10.1055/a-2267-9473 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Benedikt Schnarkowski Hans-Jonas Meyer Source Type: research
Criteria for inpatient diagnostic and treatment of patients with lung cancer, mesothelioma or thymoma
Pneumologie. 2024 Apr;78(4):e1. doi: 10.1055/a-2278-4661. Epub 2024 Feb 28.NO ABSTRACTPMID:38608660 | DOI:10.1055/a-2278-4661 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Nikolaj Frost Claas Wesseler Bernhard W örmann Wilfried Ernst Erich Eberhardt Source Type: research
Criteria for inpatient diagnostic and treatment of patients with lung cancer, mesothelioma or thymoma
Pneumologie. 2024 Apr;78(4):233-235. doi: 10.1055/a-2227-3775. Epub 2024 Jan 4.NO ABSTRACTPMID:38608657 | DOI:10.1055/a-2227-3775 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Nikolaj Frost Claas Wesseler Bernhard W örmann Wilfried Ernst Erich Eberhardt Source Type: research
Clinical course of mild-to-moderate idiopathic pulmonary fibrosis during therapy with pirfenidone: Results of the non-interventional study AERplus
CONCLUSIONS: The results of this study are in line with the established benefit-risk profile of pirfenidone. Therefore, pirfenidone can be considered a valuable treatment option to slow disease progression in mild-to-moderate idiopathic pulmonary fibrosis. NCT02622477.PMID:38608658 | PMC:PMC11014748 | DOI:10.1055/a-2267-2074 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Jens Schreiber Wolfgang Sch ütte Wolfgang Koerber Bernd Seese Dirk Koschel Kathrin Neuland Christian Groh é Source Type: research
Test Your Knowledge
Pneumologie. 2024 Apr;78(4):276-278. doi: 10.1055/a-2267-9473. Epub 2024 Apr 12.NO ABSTRACTPMID:38608659 | DOI:10.1055/a-2267-9473 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Benedikt Schnarkowski Hans-Jonas Meyer Source Type: research
Criteria for inpatient diagnostic and treatment of patients with lung cancer, mesothelioma or thymoma
Pneumologie. 2024 Apr;78(4):e1. doi: 10.1055/a-2278-4661. Epub 2024 Feb 28.NO ABSTRACTPMID:38608660 | DOI:10.1055/a-2278-4661 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Nikolaj Frost Claas Wesseler Bernhard W örmann Wilfried Ernst Erich Eberhardt Source Type: research
Criteria for inpatient diagnostic and treatment of patients with lung cancer, mesothelioma or thymoma
Pneumologie. 2024 Apr;78(4):233-235. doi: 10.1055/a-2227-3775. Epub 2024 Jan 4.NO ABSTRACTPMID:38608657 | DOI:10.1055/a-2227-3775 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Nikolaj Frost Claas Wesseler Bernhard W örmann Wilfried Ernst Erich Eberhardt Source Type: research
Clinical course of mild-to-moderate idiopathic pulmonary fibrosis during therapy with pirfenidone: Results of the non-interventional study AERplus
CONCLUSIONS: The results of this study are in line with the established benefit-risk profile of pirfenidone. Therefore, pirfenidone can be considered a valuable treatment option to slow disease progression in mild-to-moderate idiopathic pulmonary fibrosis. NCT02622477.PMID:38608658 | PMC:PMC11014748 | DOI:10.1055/a-2267-2074 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Jens Schreiber Wolfgang Sch ütte Wolfgang Koerber Bernd Seese Dirk Koschel Kathrin Neuland Christian Groh é Source Type: research
Test Your Knowledge
Pneumologie. 2024 Apr;78(4):276-278. doi: 10.1055/a-2267-9473. Epub 2024 Apr 12.NO ABSTRACTPMID:38608659 | DOI:10.1055/a-2267-9473 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Benedikt Schnarkowski Hans-Jonas Meyer Source Type: research
Criteria for inpatient diagnostic and treatment of patients with lung cancer, mesothelioma or thymoma
Pneumologie. 2024 Apr;78(4):e1. doi: 10.1055/a-2278-4661. Epub 2024 Feb 28.NO ABSTRACTPMID:38608660 | DOI:10.1055/a-2278-4661 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Nikolaj Frost Claas Wesseler Bernhard W örmann Wilfried Ernst Erich Eberhardt Source Type: research
Criteria for inpatient diagnostic and treatment of patients with lung cancer, mesothelioma or thymoma
Pneumologie. 2024 Apr;78(4):233-235. doi: 10.1055/a-2227-3775. Epub 2024 Jan 4.NO ABSTRACTPMID:38608657 | DOI:10.1055/a-2227-3775 (Source: Pneumologie)
Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Nikolaj Frost Claas Wesseler Bernhard W örmann Wilfried Ernst Erich Eberhardt Source Type: research
